Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Combining antibiotics to tackle antimicrobial resistance

An Author Correction to this article was published on 09 April 2025

This article has been updated

Combining antibiotics remains a promising approach to treat patients and to prevent the emergence of antimicrobial resistance

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Combination antibiotics for AMR.

Change history

References

  1. AMR-X Collaborators. Lancet Microbe 5, e500–e507 (2024).

    Article  Google Scholar 

  2. Antimicrobial Resistance Collaborators et al. Lancet 399, 629–655 (2022).

  3. Kerantzas, C. A. & Jacobs, W. R. mBio 8, e01586–16 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Poespoprodjo, J. R., Douglas, N. M., Ansong, D., Kho, S. & Anstey, N. M. Lancet 402, 2328–2345 (2023).

    Article  PubMed  Google Scholar 

  5. Goldstein, B. P. J. Antibiot. 67, 625–630 (2014).

    Article  CAS  Google Scholar 

  6. Docobo-Pérez, F. et al. Antimicrob. Agents Chemother. 59, 5602–5610 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Howard, A. et al. Lancet Infect. Dis. 24, e47–e58 (2024).

    Article  PubMed  Google Scholar 

  8. Darlow, C. A. et al. Antimicrob. Agents Chemother. 65, e00293–21 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Abou Fayad, A. et al. BMJ Glob. Health 7, e010863 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gowrisankar, G. et al. Sci. Data 4, 170135 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Nellums, L. B. et al. Lancet Infect. Dis. 18, 796–811 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bokhary, H., Pangesti, K. N. A., Rashid, H., Abd El Ghany, M. & Hill-Cawthorne, G. A. Trop. Med. Infect. Dis. 6, 11 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Higgins, K. Regulatory Overview of Adequate and Well-Controlled Studies in TB Regimen Development (FDA, 2018).

  14. Paul, M. et al. Lancet Infect. Dis. 18, 391–400 (2018).

    Article  CAS  PubMed  Google Scholar 

  15. Walker, A. S. et al. Lancet Infect. Dis. 21, e175–e181 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported in part by UKRI 107136 36348 (to W.H.) and Wellcome Trust grant ref: 226691/Z/22/Z (to W.H., A.H. and A.G.). C.A.D. is funded by the NIHR (Award Ref. CL-2022-07-001). Pre-X refers to a movement of scientists who are interested in feeding the pipeline of new antibacterial agents towards agencies such as CARB-X, as well as optimizing the use and combinations of existing agents).

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to William Hope.

Ethics declarations

Competing interests

W.H. holds or has recently held research grants with UKRI, EU (FP7, IMI-1, IMI-2), Wellcome, F2G, Spero Therapeutics, Antabio, Pfizer, Allecra, Bugworks, Phico Therapeutics, BioVersys and the Global Antibiotic Research and Development Partnership (GARDP). He is (or has recently been) a consultant for Appili Therapeutics, F2G, Spero Therapeutics, Pfizer, GSK, Phico Therapeutics, Pulmocide and Mundipharma Research Ltd. He was a member of the Specialist Advisory Committee for GARDP (2020–2023), a member of the British Society for Antimicrobial Chemotherapy (BSAC) Breakpoint Committee (2020–2023), a member of Health Technology Appraisal (HTA) Prioritisation Committee for Hospital Care (2022–2024) and was the Specialty National Co-lead for Infection for the National Institute of Health Research (NIHR) (2020–2024). I.B. was Chief Data Scientist Advisory for AstraZeneca (2019–2023). S.N. is an employee of Johnson and Johnson; her views are her own and do not necessarily represent those of her employer. A.H. declares past personal consulting work for Pfizer outside the submitted work, and a donation from Pfizer to the University of Liverpool for a public and professional engagement project outside the submitted work. The other authors declare no competing interests.

Peer review

Peer review information

Nature Microbiology thanks the anonymous reviewers for their contribution to the peer review of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hope, W., Nambiar, S., O’Brien, S. et al. Combining antibiotics to tackle antimicrobial resistance. Nat Microbiol 10, 813–816 (2025). https://doi.org/10.1038/s41564-025-01969-x

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41564-025-01969-x

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing